AllerGen’s Final Network Report, and some thank yous

AllerGen’s Final Network Report, and some thank yous

Final Network Report
Highlight Summary

Over 15 years as a national Networks of Centres of Excellence (NCE), AllerGen invested over $51M in 220 research projects; trained 1,763 Highly Qualified Personnel (HQP) students and trainees; partnered with 651 organizations across sectors to leverage $128.6M; generated 6,730 scientific publications; and had its research featured in major national and international media over 4,000 times.

On June 29, 2020, AllerGen submitted its final NCE Statistical Reporting package, including a Network Final Report, which details these accomplishments.

We are pleased to share this report with you, as well as a two-page highlight summary.

Click on the images to access the documents

AllerGen extends its deep appreciation to the Network’s investigators, trainees, partners, Board of Directors, Research Management Committee (RMC), Advisory Committee members, and the Network’s leadership and administrative team. The accomplishments of the past 15 years are a testament to their ongoing commitment and contributions to the successful fulfillment of AllerGen’s NCE mandate and mission.

We also sincerely thank the following individuals, who retired from the AllerGen Board of Directors on June 30, 2020, for their valuable contributions:

  • Dr. Judah Denburg, Professor & William J. Walsh Chair in Medicine, Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University (AllerGen NCE Scientific Director to March 31, 2020)
  • Dr. Charles Frankish, MD, FRCPC, Clinician, Kanata Allergy Services
  • Mr. Jean-François Leprince, Managing Director, CTI Life Sciences
  • Dr. Donald Stark, MD, FRCPC, Professor, Department of Medicine, The University of British Columbia
  • Dr. Lorne Tyrrell, Distinguished University Professor & GSK Chair in Virology, University of Alberta

We also wish to recognize and thank Administrative Centre staff Ms. April O’Connell and Ms. Graziella Infanti as they conclude their years of dedicated and outstanding service, effective today. April served as AllerGen’s Research Manager from 2012-2020; Graziella as AllerGen’s Executive Assistant from 2015-2020.

Working together, we have transformed the landscape of allergic and respiratory disease in Canada and left a lasting legacy of national and global impacts benefiting those living with and caring for persons living with allergy, asthma and related immune disease.

Sincerely,

Pieter Cullis

Board Chair

Diana Royce

President & CEO